HUTCHMED (China) (HMDCF) Retained Earnings (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Retained Earnings came in at $1.5 billion in Q2 2026, up 0.77% year-over-year from $1.5 billion in Q2 2025, and little changed quarter-over-quarter from $1.5 billion in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Retained Earnings (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Retained Earnings for 12 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Retained Earnings rose 0.77% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 0.77% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, changed N/A from the prior year.
- Retained Earnings was $1.5 billion for Q2 2026 at HUTCHMED (China), roughly flat from $1.5 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.5 billion in Q2 2026 and troughed at $1.5 billion in Q2 2022.
- A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 5.09% in 2022, down 0.53% in 2022.
- Over 5 years, Retained Earnings stood at $1.5 billion in 2022, then rose by 0.6% to $1.5 billion in 2023, then grew by 0.08% to $1.5 billion in 2024, then increased by 1.75% to $1.5 billion in 2025, then increased by 0.36% to $1.5 billion in 2026.
- The last three Retained Earnings figures came in at $1.5 billion (Q2 2026), $1.5 billion (Q4 2025), and $1.5 billion (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | 5.13 Bn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 1.54 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Bn |
| Dec 31, 2025 | 1.53 Bn |
| Jun 30, 2025 | 1.53 Bn |
| Jun 30, 2024 | 1.51 Bn |
| Jun 30, 2023 | 1.51 Bn |
| Dec 31, 2022 | 1.50 Bn |
| Jun 30, 2022 | 1.48 Bn |
| Dec 31, 2021 | 1.51 Bn |
| Jun 30, 2021 | 1.41 Bn |
| Mar 31, 2021 | 808.78 Mn |
| Dec 31, 2020 | 822.46 Mn |
| Jun 30, 2020 | 618.13 Mn |
| Dec 31, 2019 | 514.90 Mn |
| Sep 30, 2019 | 512.59 Mn |
| Jun 30, 2019 | 510.70 Mn |
| Mar 31, 2019 | 508.55 Mn |
| Dec 31, 2018 | 505.59 Mn |
| Jun 30, 2018 | 497.52 Mn |
| Dec 31, 2017 | 496.96 Mn |
| Jun 30, 2017 | 208.66 Mn |